Sustained-release of erythropoietin using a novel injectable thermosensitive hydrogel:


Journal

Pharmaceutical development and technology
ISSN: 1097-9867
Titre abrégé: Pharm Dev Technol
Pays: England
ID NLM: 9610932

Informations de publication

Date de publication:
Apr 2021
Historique:
pubmed: 5 2 2021
medline: 3 11 2021
entrez: 4 2 2021
Statut: ppublish

Résumé

In the current study erythropoietin (EPO) loaded trimethyl chitosan/tripolyphosphate nanoparticles-embedded in a thermosensitive hydrogel was prepared. The influence of the main experimental factors on the properties of EPO-loaded nanoparticles were evaluated using a two-factors central composite design and the optimized formulation was then freeze dried. Sodium dodecyl sulfate-page and circular dichroismspectroscopy were used to confirm the structural stability of EPO following encapsulation and freeze drying. Rheological properties, and the release rate of EPO from the hydrogel were examined. Mean particle size, zeta potential, and entrapment efficiency of the optimized EPO-loaded nanoparticles were confirmed 151.5 ± 16 nm, 11.5 ± 1.8 mV, and 78.5 ± 5.9%, respectively. The hydrogel containing nanoparticles existed as a solution at room temperature converted to a semisolid upon increasing the temperature to 35 ± 1.2 °C and demonstrated controlled release of EPO for more than 10 days. The stability of EPO in the hydrogel system was further investigated using in vivo biological activity assay and the result revealed relative potency of 0.85 as calibrated with standard EPO. Finally, a single injection of the EPO-loaded nanoparticles-embedded in the hydrogel administered to Sprague-Dawley rats resulted in elevated reticulocytes for about 20 days compared to control group received blank hydrogel.

Identifiants

pubmed: 33538616
doi: 10.1080/10837450.2021.1883059
doi:

Substances chimiques

Delayed-Action Preparations 0
Drug Carriers 0
EPO protein, human 0
Hydrogels 0
chitosan-tripolyphosphate 0
Erythropoietin 11096-26-7
Chitosan 9012-76-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

412-421

Auteurs

Mahboubeh Rezazadeh (M)

Department of Pharmaceutics, Novel Drug Delivery System Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.

Vajihe Akbari (V)

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.

Jaleh Varshosaz (J)

Department of Pharmaceutics, Novel Drug Delivery System Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.

Parisa Karbasizadeh (P)

Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.

Mohsen Minaiyan (M)

Department of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH